Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing
Market News Market Pulse Stocks News ETF News Crypto News

vTv Therapeutics Inc.

Contributing Author

Recent Articles by vTv Therapeutics Inc.

Oct-07
vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease VTVT GlobeNewswire
Oct-06
vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026 VTVT GlobeNewswire
Oct-05
vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D) VTVT GlobeNewswire
Sep-15
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) VTVT GlobeNewswire
Sep-02
vTv Therapeutics to Participate in September Investor Conferences VTVT GlobeNewswire
Aug-19
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) VTVT GlobeNewswire
Aug-06
vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update VTVT GlobeNewswire
Jul-28
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) VTVT GlobeNewswire
Jul-02
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) VTVT GlobeNewswire
Jun-02
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) VTVT GlobeNewswire
May-13
vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update VTVT VTVT +21.36% GlobeNewswire
May-08
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) VTVT GlobeNewswire
May-07
vTv Therapeutics to Participate in Upcoming May Investor Conferences VTVT GlobeNewswire
Apr-07
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) VTVT GlobeNewswire
Mar-16
vTv Therapeutics to Participate in the 38th Annual ROTH Conference VTVT +14.57% GlobeNewswire
Mar-10
vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update VTVT GlobeNewswire
Feb-13
vTv Therapeutics to Participate in Upcoming Investor Conferences VTVT -7.18% GlobeNewswire
Feb-02
vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737 VTVT +8.19% GlobeNewswire
Dec-18
vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health VTVT GlobeNewswire
Nov-06
vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update VTVT +5.07% GlobeNewswire
Oct-09
vTv Therapeutics Announces New Appointments to its Scientific Advisory Board VTVT GlobeNewswire
Sep-15
vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting VTVT GlobeNewswire
Sep-03
UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences VTVT GlobeNewswire
Sep-03
vTv Therapeutics to Participate in Upcoming September Investor Conferences VTVT GlobeNewswire
Sep-02
vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund VTVT +13.30% GlobeNewswire
Aug-12
vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update VTVT -6.35% GlobeNewswire
Aug-11
vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin VTVT +10.52% GlobeNewswire
Aug-07
vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes VTVT GlobeNewswire
Jun-11
vTv Therapeutics to Participate in the H.C. Wainwright "HCW@Home" Series VTVT GlobeNewswire
May-19
vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin VTVT GlobeNewswire
May-15
vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update VTVT +5.16% VTVT -6.16% GlobeNewswire
May-15
vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes VTVT +5.16% VTVT -6.16% GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)